Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

European Quality of Care Pathways Study on Chronic Obstructive Pulmonary Disease (COPD) (EQCP-COPD)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Katholieke Universiteit Leuven
University of Eastern Piedmont
Information provided by:
European Pathway Association
ClinicalTrials.gov Identifier:
NCT00962468
First received: August 19, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
  Purpose

Care pathways, a complex intervention to (re)organise, standardize and evaluate care processes, are used worldwide and in different kinds of settings. Although their international use, the impact is unclear. The European Quality of Care Pathways Study is the first international cluster Randomized Controlled Trial on the effect of care pathways for COPD patients.

The hypothesis is that teams who work with care pathways for COPD patients deliver care that is more compliant to evidence based key interventions, have better patient outcomes and higher scores on team indicators than teams who do not work with care pathways.


Condition Intervention
Pulmonary Disease, Chronic Obstructive
Other: COPD evidence based care pathway

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: The European Quality of Care Pathways Study: The Impact of a Care Pathway for Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) : an International Cluster Randomized Controlled Trial."

Resource links provided by NLM:


Further study details as provided by European Pathway Association:

Primary Outcome Measures:
  • Readmission rate [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Mortality [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Length of stay [ Time Frame: in hospital ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 400
Study Start Date: May 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pathway
A care pathway will be implemented in this experimental group.
Other: COPD evidence based care pathway
A care pathways, as complex intervention, will be implemented.
Other Names:
  • pathway
  • care pathway
  • clinical pathway
  • critical pathway
  • integrated care pathway
No Intervention: Usual care
Usual care will be provided.

Detailed Description:

Healthcare is changing towards more patient focused care. The organization of the care process related to quality, efficiency and accessibility is one of the main areas of interest within the next years for clinicians, healthcare managers and policy makers. A main method to (re)organize a care process is the development and implementation of a care pathway. Care pathways, also known as clinical pathways or critical pathways, are used worldwide for a variety of patient groups. The European Pathway Association (E-P-A) defines a care pathway as: "A complex intervention for the mutual decision making and organization of predictable care for a well-defined group of patients during a well defined period. Defining characteristics of pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice and patient expectations; the facilitations of the communication and coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of relevant resources".

Very few prospective studies have been performed and published on the impact of pathways on quality and efficiency of care. The European Quality of Care Pathways (EQCP)-study will involve exacerbation of Chronic Obstructive Pulmonary Disease (COPD) to evaluate pathway effectiveness. Literature shows that adherence to international guidelines with regard to inhospital management of COPD exacerbation is low, especially in non pharmacological treatment.11-19 Currently, only three non-randomized trials about the impact of a care pathway for inpatient management of COPD exacerbation are published. The studies are conducted between 1995 and 2001, and the methodology is doubtful. However the studies indicate that a COPD exacerbation care pathway improves performance with regard to diagnostic assessment and use of standing orders, and that it diminishes the number of rehospitalisation, shortens length of stay (LOS) and reduces mortality.

In the context of the high volume of hospitalized COPD patients, high costs and high risk, and the complex coordination of care among multiple caregivers, a care pathway could enhance the quality of care in these patients by improving patient outcomes, promoting patient safety, increasing patient satisfaction, improving multidisciplinary teamwork and optimizing the use of resources.

The goal of the European Quality of Care Pathways (EQCP) study is:

  • To evaluate the care pathway effectiveness in acute hospitals and their immediate link with primary care;
  • To evaluate the effect of care pathways on team processes and team perceived organization of care.
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion criteria on cluster level are:

  1. Written agreement to participate in the study;
  2. Agreement that a care pathway for COPD will not be developed and used within the time frame of the study when randomized in the control group.

Inclusion criteria on patient level are:

  1. Written informed consent;
  2. All consecutive admissions with COPD exacerbation;
  3. Hospitalization for at least 48 hours;
  4. Moderate, severe or very severe COPD;
  5. Each patient will be included only once in the study at initial hospitalization, even if the patient had been hospitalized more than once.

Exclusion Criteria:

Exclusion criteria on patient level:

  1. Admission required to intensive care unit;
  2. Need for Invasive Positive Pressure Ventilation (IPVV).

Inclusion criteria on multidisciplinary team level:

  1. Team members are involved in direct patient care responsibilities for COPD;
  2. Minimum representation of the core disciplines according to COPD literature;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00962468

Sponsors and Collaborators
European Pathway Association
Katholieke Universiteit Leuven
University of Eastern Piedmont
Investigators
Study Director: Kris Vanhaecht, PhD Katholieke Universiteit Leuven
Principal Investigator: Walter Sermeus, PhD Katholieke Universiteit Leuven
Principal Investigator: Massimiliano Panella, PhD Amedeo Avogadro University of Eastern Piemont
  More Information

Additional Information:
No publications provided by European Pathway Association

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Kris Vanhaecht, Secretary General, European Pathway Association, ivzw
ClinicalTrials.gov Identifier: NCT00962468     History of Changes
Other Study ID Numbers: EPA-EQCP001
Study First Received: August 19, 2009
Last Updated: August 19, 2009
Health Authority: Belgium: Institutional Review Board

Keywords provided by European Pathway Association:
Pulmonary Disease, Chronic Obstructive
Critical Pathway
Cluster Randomized Controlled Trial
Safety
Efficiency

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 27, 2014